Allogeneic (not from the subject) human umbilical cord tissue-derived stem cells administered intravenously (IV) in a series of 4 infusions every 3 months over the course of one year is safe and will induce a therapeutic effect in autism patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Stem Cell Institute
Panama City, Panama
Number of participants with adverse events
Time frame: 89 weeks
Number of participants with a change in disability as measured by the Autism Treatment Evaluation Checklist (ATEC)
Time frame: 13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks
Number of participants with a change in disability as measured by the Childhood Autism Rating Scale (CARS)
Time frame: 13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks
Change from baseline macrophage-derived chemokine (MDC)
Time frame: 13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks
Change from baseline thymus and activation-regulated chemokine (TARC)
Time frame: 13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.